|
|
Article: Nastech Initiates Clinical Development of Rapid Acting Insulin Nasal Spray for Diabetes.
- Article from:
- PR Newswire
- Article date:
- September 19, 2006
CopyrightCOPYRIGHT 2006 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
- Phase I pharmacokinetic study to compare Nastech's intranasal insulin to injectable insulin and Exubera(R) (insulin human [rDNA origin]) Inhalation Powder -
BOTHELL, Wash., Sept. 19 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical Company Inc. announced today the initiation of a Phase I pharmacokinetic study designed to evaluate the safety, bioavailability and glucose response of Nastech's proprietary, rapid acting intranasal insulin formulation. The study will compare Nastech's intranasal formulation to an approved injectable product and to a recently approved new dosage form, Exubera(R) (insulin human [rDNA origin]) Inhalation Powder. Nastech's insulin ...